Genenta Science SpA ADR Total Liabilities
Genenta Science SpA ADR total liabilities. Based on the latest financial reports, Genenta Science SpA ADR (GNTA) has total liabilities worth $10.05 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Genenta Science SpA ADR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genenta Science SpA ADR (2019–2025)
Total liabilities of Genenta Science SpA ADR from 2019 to 2025. This chart illustrates how Genenta Science SpA ADR's total liabilities have evolved over time, based on quarterly financial data.
Genenta Science SpA ADR Competitors by Total Liabilities
The table below lists competitors of Genenta Science SpA ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Carlin Gold Corporation
V:CGD
|
Canada | CA$44.37K |
|
Esotiq & Henderson S.A.
WAR:EAH
|
Poland | zł135.06 Million |
|
Y&G Corp Bhd
KLSE:7003
|
Malaysia | RM605.03 Million |
|
Raytech Holding Limited Ordinary Shares
NASDAQ:RAY
|
USA | $86.46 Million |
|
Ark Restaurants Corp
NASDAQ:ARKR
|
USA | $97.34 Million |
|
Enzo Biochem Inc
NYSE:ENZ
|
USA | $20.12 Million |
|
Watos Corea Co. Ltd
KQ:079000
|
Korea | ₩4.98 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Genenta Science SpA ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Genenta Science SpA ADR.
Liquidity & Leverage Metrics
Genenta Science SpA ADR Total Liabilities Ratios Explained
Genenta Science SpA ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genenta Science SpA ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genenta Science SpA ADR (2019–2025)
The table below shows the annual total liabilities of Genenta Science SpA ADR from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.05 Million | +331.59% |
| 2024-12-31 | $2.33 Million | +21.59% |
| 2023-12-31 | $1.91 Million | -16.73% |
| 2022-12-31 | $2.30 Million | +97.29% |
| 2021-12-31 | $1.17 Million | -50.41% |
| 2020-12-31 | $2.35 Million | -5.87% |
| 2019-12-31 | $2.50 Million | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more